Roberts Wealth Advisors LLC Reduces Stake in Zoetis Inc. $ZTS

Roberts Wealth Advisors LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 26.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,257 shares of the company’s stock after selling 5,240 shares during the period. Roberts Wealth Advisors LLC’s holdings in Zoetis were worth $1,794,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Zoetis in the second quarter valued at approximately $809,491,000. Diamond Hill Capital Management Inc. purchased a new stake in shares of Zoetis during the 3rd quarter worth approximately $394,010,000. Nordea Investment Management AB boosted its holdings in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after buying an additional 2,179,578 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Zoetis by 83.4% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock valued at $394,746,000 after buying an additional 1,227,085 shares in the last quarter. Finally, Corient Private Wealth LLC grew its position in shares of Zoetis by 85.9% in the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock valued at $400,619,000 after buying an additional 1,191,840 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.6%

NYSE:ZTS opened at $116.65 on Thursday. Zoetis Inc. has a 12-month low of $113.30 and a 12-month high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock’s 50 day simple moving average is $123.79 and its 200-day simple moving average is $129.67. The firm has a market cap of $49.24 billion, a P/E ratio of 19.38, a PEG ratio of 1.77 and a beta of 0.95.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period last year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. Zoetis’s payout ratio is presently 35.22%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ZTS shares. UBS Group set a $136.00 price target on shares of Zoetis in a research report on Thursday, January 29th. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Bank of America upped their target price on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Finally, The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research note on Monday, December 15th. Six research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.